Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 31, 2023
A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 3, 2023
Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 3, 2023
A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2023
A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2023
A phase IIa randomized, double-blinded clinical trial of naproxen or aspirin for cancer immune interception in Lynch syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 8, 2023
A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 17, 2023
Antenatal Anxiety and Dyadic Immune Risk (ADIR) Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 21, 2023
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 5, 2023
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 5, 2023